Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd working capital to net assets ratio. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Working Capital to Net Assets ratio of 60.5% as of September 2025. Working capital of CN¥1.65 Billion (current assets of CN¥1.77 Billion minus current liabilities of CN¥119.95 Million) is measured against net assets of CN¥2.73 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
Working capital to net assets ratio of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024. This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 16 annual periods from 2009 to 2024. As of September 2025, the ratio stands at 60.5%, reflecting working capital of CN¥1.65 Billion against net assets of CN¥2.73 Billion CNY. See Zhejiang Wolwo Bio-Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2009–2024)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd working capital to net assets ratio by year from 2009 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 300357 current and non-current assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 59.7% | CN¥1.47 Billion | CN¥2.46 Billion | CN¥1.65 Billion | CN¥182.58 Million | ▼ -0.7 pp |
| 2023 | 60.5% | CN¥1.39 Billion | CN¥2.30 Billion | CN¥1.57 Billion | CN¥177.04 Million | ▼ -7.3 pp |
| 2022 | 67.8% | CN¥1.37 Billion | CN¥2.03 Billion | CN¥1.48 Billion | CN¥102.75 Million | ▼ -0.9 pp |
| 2021 | 68.7% | CN¥1.23 Billion | CN¥1.80 Billion | CN¥1.34 Billion | CN¥108.00 Million | ▼ -4.3 pp |
| 2020 | 73.0% | CN¥1.12 Billion | CN¥1.53 Billion | CN¥1.17 Billion | CN¥55.42 Million | ▼ -0.2 pp |
| 2019 | 73.2% | CN¥989.97 Million | CN¥1.35 Billion | CN¥1.05 Billion | CN¥60.03 Million | ▲ +0.5 pp |
| 2018 | 72.7% | CN¥724.04 Million | CN¥995.42 Million | CN¥781.66 Million | CN¥57.62 Million | ▼ -3.9 pp |
| 2017 | 76.7% | CN¥614.30 Million | CN¥801.26 Million | CN¥656.50 Million | CN¥42.20 Million | ▼ 0.0 pp |
| 2016 | 76.7% | CN¥502.75 Million | CN¥655.58 Million | CN¥539.21 Million | CN¥36.46 Million | ▼ -2.2 pp |
| 2015 | 78.9% | CN¥459.65 Million | CN¥582.91 Million | CN¥484.28 Million | CN¥24.63 Million | ▼ -5.0 pp |
| 2014 | 83.9% | CN¥430.72 Million | CN¥513.55 Million | CN¥446.92 Million | CN¥16.20 Million | ▲ +11.2 pp |
| 2013 | 72.7% | CN¥183.05 Million | CN¥251.92 Million | CN¥195.08 Million | CN¥12.04 Million | ▲ +2.7 pp |
| 2012 | 70.0% | CN¥126.89 Million | CN¥181.38 Million | CN¥134.85 Million | CN¥7.96 Million | ▲ +8.8 pp |
| 2011 | 61.2% | CN¥78.06 Million | CN¥127.61 Million | CN¥94.99 Million | CN¥16.92 Million | ▲ +15.4 pp |
| 2010 | 45.8% | CN¥41.41 Million | CN¥90.44 Million | CN¥57.95 Million | CN¥16.54 Million | ▼ -17.1 pp |
| 2009 | 62.9% | CN¥70.40 Million | CN¥111.89 Million | CN¥75.47 Million | CN¥5.07 Million | — |